A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 24 Jan 2017 Planned primary completion date changed from 1 Oct 2013 to 1 Mar 2017.
- 19 May 2016 Primary endpoint has been met. (Overall survival), as per an article published in the Cancer.
- 19 May 2016 Results published in the Cancer